Arovella advances ALA-101 program with CRO appointment and Phase 1 trial preparations

“After positive feedback from FDA during our recent Type D meeting, we are excited to initiate start-up activities for the phase 1 clinical trial and are delighted to have found an excellent partner in SAPRO,” said Michael Baker, Chief Executive Officer and Managing Director of Arovella. …